CoChat

High performance plasma amyloid-β biomarkers for Alzheimer's disease

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease, which are expected to be most efficacious at the earliest and mildest stages of the disease, supportive biomarker information is necessary. The only validated methods for identifying amyloid-β deposition in the brain-the earliest pathological signature of Alzheimer's disease-are amyloid-β positron-emission tomography (PET) imaging or measurement of amyloid-β in cerebrospinal fluid. Therefore, a minimally invasive, cost-effective blood-based biomarker is desirable. Despite much effort, to our knowledge, no study has validated the clinical utility of blood-based amyloid-β markers. Here we demonstrate the measurement of high-performance plasma amyloid-β biomarkers by immunoprecipitation coupled with mass spectrometry. The ability of amyloid-β precursor protein (APP) 669-711 /amyloid-β (Aβ) 1-42 and Aβ 1-40 /Aβ 1-42 ratios, and their composites, to predict individual brain amyloid-β-positive or -negative status was determined by amyloid-β-PET imaging and tested using two independent data sets: a discovery data set (Japan, n = 121) and a validation data set (Australia, n = 252 including 111 individuals diagnosed using 11 C-labelled Pittsburgh compound-B (PIB)-PET and 141 using other ligands). Both data sets included cognitively normal individuals, individuals with mild cognitive impairment and individuals with Alzheimer's disease. All test biomarkers showed high performance when predicting brain…

Overview

Integrity signals

Registry

Crossref · 10.1038/nature25456

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

9 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 47 references

Research works printed but not linked: 1

  1. Rogers, M. B. Are CSF Assays Finally Ready for Prime Time? Alzforum https://www.alzforum.org/news/conference-coverage/are-csf-assays-finally-ready-prime-time (2017)

Cited by

See all 1,681

Metadata

Authors
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., Tomita, T., Matsuzaki, K., Ishii, K., Ishii, K., Arahata, Y., Iwamoto, S., Ito, K., Tanaka, K., Masters, C. L., & Yanagisawa, K.
Affiliations
  • National Center for Geriatrics and Gerontology (JP)
  • Shimadzu (Japan) (JP)
  • The University of Melbourne (AU)
  • Commonwealth Scientific and Industrial Research Organisation (AU)
  • Edith Cowan University (AU)
  • The University of Tokyo (JP)
  • Kyoto University (JP)
  • Tokyo Metropolitan Institute of Gerontology (JP)
  • National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology (JP)
Corresponding author
Yanagisawa, Katsuhiko
Venue
Nature
Published
2018-01-31
Volume
554
Issue
7691
Pages
249-254
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2785757836
Cited by
1,681
References
47
Citations by year
2026: 137 · 2025: 166 · 2024: 204 · 2023: 203 · 2022: 227 · 2021: 233 · 2020: 236 · 2019: 174 · 2018: 97
FWCI
127.20
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Research Online (Edith Cowan University) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • National Center for Geriatrics and Gerontology
  • Japan Society for the Promotion of Science (15H02492)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Physical Sciences › Chemistry › Spectroscopy › Mass Spectrometry Techniques and Applications
Keywords
Alzheimer's disease, amyloid-beta deposition, blood-based biomarkers, immunoprecipitation mass spectrometry, 11C-Pittsburgh compound B, cerebrospinal fluid amyloid-beta
MeSH terms
Aged, Alzheimer Disease, Australia, Brain, Cost-Benefit Analysis, Female, Humans, Japan, Male, Peptide Fragments, Mass Spectrometry, Reproducibility of Results, Biomarkers, Case-Control Studies, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Immunoprecipitation, Positron-Emission Tomography, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High performance plasma amyloid-β biomarkers for Alzheimer's disease. https://app.cochat.ai/papers/10.1038/nature25456
The paper
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., Tomita, T., Matsuzaki, K., Ishii, K., Ishii, K., Arahata, Y., Iwamoto, S., Ito, K., Tanaka, K., Masters, C. L., & Yanagisawa, K. (2018). High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature. https://doi.org/10.1038/nature25456

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.